The UK Rare Disease Framework

Principles of the UK Rare Diseases Framework

“All 4 UK nations have signed up to the UK Rare Diseases Framework and have therefore agreed to collaborate to achieve the outcomes set out above. However, as health is a devolved matter, each nation will deliver these aims in a way that is most effective for their respective populations. Therefore, each nation will set out an action plan detailing the steps they will take to meet the aims of the framework within their own arrangements. In order to ensure cross-border collaboration and maximise the benefits of the framework for the rare disease community, each nation will follow the below core principles when delivering action plans and implementing the framework.

Each nation will: Deliver the aims of the UK Rare Diseases Framework under each of the priorities and underpinning themes:

1. Ensuring patients get the right diagnosis faster
2. Increasing awareness of rare diseases among healthcare professionals
3. Better coordination of care
4. Improving access to specialist care, treatments, and drugs

Underpinning themes:
• Patient voice
• National and international collaboration
• Pioneering research
• Digital, data, and technology
• Wider policy alignment

Consider where action plans can contain specific and measurable commitments under each focus area and regularly review commitments (every 1 to 2 years). Develop policy commitments with expertise, in close collaboration with patients and others living and working with rare diseases.

The UK Rare Diseases Framework 21 Ensure any impacts on health inequalities are considered when developing action plans. Ensure that the experiences of rare disease patients during the COVID-19 pandemic are reflected in the development of action plans and implementation of framework priorities and themes. Ensure that the voice of the rare diseases community is recognised across the system and that work as part of the UK Rare Diseases Framework is aligned with other relevant policy development, such as mental health and social care. Work collaboratively across nations to share knowledge and best practice. Review progress made towards the aims of the framework every 5 years and update priorities when necessary”.


0 0 votes
Article Rating
Notify of
Inline Feedbacks
View all comments

Related Post

Cardiac phenotype in ATP1A3-related syndromes: A multicentre cohort studyCardiac phenotype in ATP1A3-related syndromes: A multicentre cohort study

 View ORCID Profile Simona Balestrini, Mohamad A Mikati, Reyes Alvarez Garcia-Roves,  View ORCID Profile Michael Carboni, Arsen S Hunanyan, Bassil Kherallah, Melissa McLean, Lyndsey Prange, Elisa De Grandis, Alessandra Gagliardi,  View ORCID Profile Livia Pisciotta, Michela Stagnaro, Edvige Veneselli, Jaume Campistol, Carmen Fons, Leticia Pias-Peleteiro,  View

‘AHC and ATP1A3 Natural History Study’ Q&A session with Dr. Katerina Vezyroglou‘AHC and ATP1A3 Natural History Study’ Q&A session with Dr. Katerina Vezyroglou

Thank you to everyone who joined in this helpful Question & Answer session in November of last year with Dr. Katerina Vezyroglou on her research work. As promised, we have included the link to the recorded zoom session for those of you who were unable to attend the event.    We hope you find this helpful and as in the session,  Dr. Vezyrouglou is very happy to hear from anyone who would like to ask  any more questions. All questions are welcome.    As discussed in the zoom chat, this project also feeds into the OBSERV AHC natural history study involving many international centers.  

Would love your thoughts, please comment.x